AlphaStocks
7.0
Consider Buy

BRISTOL MYERS SQUIBB CO (BMY)

Health Care / Pharmaceuticals

S&P 500

$56.94

Above average across most dimensions. A solid candidate.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#64out of 1126 in Health Care

Is BRISTOL MYERS SQUIBB CO a Good Investment in 2026?

BRISTOL MYERS SQUIBB CO (BMY) scores 7.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates BRISTOL MYERS SQUIBB CO as Strong (8/9). However, the Graham model rates it Caution — Significantly above fair value. BRISTOL MYERS SQUIBB CO currently trades below its estimated fair value of $89, suggesting potential upside. BRISTOL MYERS SQUIBB CO ranks #64 out of 1126 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E16.5ROE38.1Market Cap117BDiv Yield4.1

Estimated Fair Value

$88.7336% below

Fair value above market price. ROE of 38% signals strong profitability. P/E of 16x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

Growth rate vs price (PEG)

Greenblatt

Attractive

Top 25% (rank 14%)

Frequently Asked Questions

Is BRISTOL MYERS SQUIBB CO (BMY) a good investment?
Based on AlphaStocks' composite analysis, BRISTOL MYERS SQUIBB CO (BMY) scores 7.0 out of 10, earning a Consider Buy rating. This places it above average across most investment dimensions. Fair value above market price. ROE of 38% signals strong profitability. P/E of 16x is moderate for this quality level.
What is BRISTOL MYERS SQUIBB CO's Piotroski F-Score?
BRISTOL MYERS SQUIBB CO's Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is BMY overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $89, BMY appears undervalued. The stock currently trades 36% below its estimated fair value. Fair value above market price. ROE of 38% signals strong profitability. P/E of 16x is moderate for this quality level.
How does BMY compare to other Health Care stocks?
BRISTOL MYERS SQUIBB CO ranks #64 out of 1126 stocks in the Health Care sector, placing it in the top 6% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about BMY?
AlphaStocks evaluates BMY using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 7.0/10.

Similar Stocks

FTIPARRAZN

Compare BMY with

BMY vs FTIBMY vs PARRBMY vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer